{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:33:39Z","timestamp":1762508019139,"version":"3.37.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hyaline membrane disease contributes majorly to preterm mortality, particularly in the developing world. There are two animal-derived surfactants available in South Africa: poractant-alfa (120\u2009mg\/1.5\u2009ml) and beractant (100\u2009mg\/4\u2009ml). At equivalent doses, studies have shown no difference in mortality or morbidity, although there are limited data from the developing world. Both surfactants have been available for use at Groote Schuur Hospital in Cape Town but due to policy change, poractant-alfa was no longer available from November 2014. Due to weight-based dosing charts, infants who were given poractant-alfa received 20% higher dosages of phospholipid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A before-and-after policy change non-experimental study was performed including infants from 2013 to 2015. Infants weighing &amp;lt;1500\u2009g were recruited by identifying them from the surfactant register and further data were obtained from patient records. Data fields included infant weight, gestation, respiratory support and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred and eight infants were included. One hundred and eight received beractant and 100 received poractant-alfa. The mean birth weight was 1031\u2009g and gestational age 28.8\u2009weeks. Seventy-nine percent of the infants received surfactant via the INSURE (intubation, surfactant and extubation) method. The combined outcome for death or bronchopulmonary dysplasia was 35.3% in the beractant group and 36% in the poractant-alfa group (p\u2009=\u20090.902). All secondary outcomes including neonatal morbidities, oxygen at 28\u2009days or length of ventilation were not statistically significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There were no significant differences in outcomes between the two groups of infants who received different surfactants at the dosages used in our unit. This is one of the few studies of this type performed in a low- and middle-income countries.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/tropej\/fmaa011","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T12:08:51Z","timestamp":1580731731000},"page":"534-541","source":"Crossref","is-referenced-by-count":5,"title":["Bovine or Porcine: Does the Type of Surfactant Matter?"],"prefix":"10.1093","volume":"66","author":[{"given":"Lize","family":"Boshoff Coyles","sequence":"first","affiliation":[{"name":"Division of Neonatal Medicine, Department of Paediatrics, University of Cape Town, Groote Schuur Hospital, Cape Town, 7925, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaseen","family":"Joolay","sequence":"additional","affiliation":[{"name":"Division of Neonatal Medicine, Department of Paediatrics, University of Cape Town, Groote Schuur Hospital, Cape Town, 7925, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-9996","authenticated-orcid":false,"given":"Lloyd","family":"Tooke","sequence":"additional","affiliation":[{"name":"Division of Neonatal Medicine, Department of Paediatrics, University of Cape Town, Groote Schuur Hospital, Cape Town, 7925, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"2020100403541626900_fmaa011-B1","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/S0140-6736(10)60703-9","article-title":"Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970\u20132010: a systematic analysis of progress towards Millennium Development Goal 4","volume":"375","author":"Rajaratnam","year":"2010","journal-title":"Lancet"},{"key":"2020100403541626900_fmaa011-B2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1742-4755-10-S1-S2","article-title":"Born too soon: the global epidemiology of 15 million preterm births","volume":"10(Suppl 1","author":"Blencowe","year":"2013","journal-title":"Reprod Health"},{"article-title":"Saving babies 2010-2011: eighth report on perinatal care in South Africa","year":"2013","author":"Pattinson","key":"2020100403541626900_fmaa011-B3"},{"key":"2020100403541626900_fmaa011-B4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0031-1295648","article-title":"A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome","volume":"29","author":"Dizdar","year":"2012","journal-title":"Am J Perinatol"},{"key":"2020100403541626900_fmaa011-B5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2004-823779","article-title":"A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants","volume":"21","author":"Ramanathan","year":"2004","journal-title":"Am J Perinatol"},{"key":"2020100403541626900_fmaa011-B6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jpeds.2013.04.053","article-title":"Comparative effectiveness of surfactant preparations in premature infants","volume":"163","author":"Trembath","year":"2013","journal-title":"J Pediatr"},{"key":"2020100403541626900_fmaa011-B7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/jp.2010.20","article-title":"Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome","volume":"30","author":"Fujii","year":"2010","journal-title":"J Perinatol"},{"key":"2020100403541626900_fmaa011-B8","first-page":"CD010249","article-title":"Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants","volume":"12","author":"Singh","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2020100403541626900_fmaa011-B9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000499361","article-title":"European Consensus Guidelines on the management of respiratory distress syndrome\u20142019 update","volume":"115","author":"Sweet","year":"2019","journal-title":"Neonatology"},{"key":"2020100403541626900_fmaa011-B10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.7196\/SAMJ.2017.v107i10.12463","article-title":"Short-term outcomes of inborn v. outborn very-low-birth-weight neonates (&lt;1 500 g) in the neonatal nursery at Groote Schuur Hospital, Cape Town, South Africa","volume":"107","author":"Gibbs","year":"2017","journal-title":"S Afr Med J"},{"key":"2020100403541626900_fmaa011-B11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0045-9380(87)90031-4","article-title":"Neonatal necrotizing enterocolitis: pathogenesis, classification, and spectrum of illness","volume":"17","author":"Kliegman","year":"1987","journal-title":"Curr Probl Pediatr"},{"key":"2020100403541626900_fmaa011-B12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12978-016-0175-3","article-title":"The Antenatal Corticosteroids Trial (ACT)\u2019s explanations for neonatal mortality\u2014a secondary analysis","volume":"13","author":"Althabe","year":"2016","journal-title":"Reprod Health"},{"key":"2020100403541626900_fmaa011-B13","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1542\/peds.2009-2131","article-title":"Prophylactic or early selective surfactant combined with nCPAP in very preterm infants","volume":"125","author":"Sandri","year":"2010","journal-title":"Pediatrics"},{"key":"2020100403541626900_fmaa011-B14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12887-015-0342-7","article-title":"A pilot study of less invasive surfactant administration in very preterm infants in a Chinese tertiary center","volume":"15","author":"Bao","year":"2015","journal-title":"BMC Pediatr"},{"key":"2020100403541626900_fmaa011-B15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2431-14-213","article-title":"The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25\u201328 weeks gestation","volume":"14","author":"Dargaville","year":"2014","journal-title":"BMC Pediatr"},{"key":"2020100403541626900_fmaa011-B16","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1136\/archdischild-2015-310299","article-title":"Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis","volume":"102","author":"Aldana-Aguirre","year":"2017","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2020100403541626900_fmaa011-B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000502610","article-title":"Surfactant administration via thin catheter: a practical guide","volume":"116","author":"Vento","year":"2019","journal-title":"Neonatology"},{"key":"2020100403541626900_fmaa011-B18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/pr.2016.203","article-title":"Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future","volume":"81","author":"Sardesai","year":"2017","journal-title":"Pediatr Res"}],"container-title":["Journal of Tropical Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/tropej\/article-pdf\/66\/5\/534\/33834115\/fmaa011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/tropej\/article-pdf\/66\/5\/534\/33834115\/fmaa011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T07:54:45Z","timestamp":1601798085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/tropej\/article\/66\/5\/534\/5770881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,29]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/tropej\/fmaa011","relation":{},"ISSN":["1465-3664"],"issn-type":[{"type":"electronic","value":"1465-3664"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,2,29]]}}}